Understanding environmental risks for blood cancers
Official title: Mapping the blood cancer exposome for environmental risk profiles of mature B-cell neoplasms
Funded at Emory University · NIH-10810720 · Data updated 2026-11-12
This study is looking at how things in our environment might increase the risk of developing certain blood cancers, like non-Hodgkin lymphoma and multiple myeloma, by analyzing blood samples from patients to find clues that could help us understand this connection better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | February 25, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $545,260 |
| NIH project number | 5R01ES032831-03 |
| Project ID | NIH-10810720 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a family history of blood cancers or those who have been exposed to various environmental factors.
✕Less likely to help
Patients with blood cancers that are not classified as mature B-cell neoplasms may not benefit from this research.
What this research studies
This research investigates how environmental factors contribute to the risk of developing mature B-cell neoplasms, such as non-Hodgkin lymphoma and multiple myeloma. By using advanced mass spectrometry techniques, the study aims to identify and characterize the cumulative environmental exposures that may influence the development of these cancers. Patients will be involved in a nested case-control study, where their blood samples will be analyzed to uncover potential biomarkers linked to these diseases. The goal is to provide a clearer understanding of how environmental factors interact with genetic predispositions to affect cancer risk.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention strategies and targeted interventions for patients at risk of blood cancers.
How similar studies have gone: While the approach of mapping the exposome is innovative, similar studies have shown promise in identifying environmental risk factors for other cancers.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Walker, Douglas Ian — Emory University
- Study coordinator: Walker, Douglas Ian
Related research
Other NIH-funded projects on the same topics.
-
Blood chemical exposures and B‑cell blood cancer risk
Researchers will use advanced blood chemical testing and AI to find environmental exposures linked to B‑cell blood cancers like non‑Hodgkin lymphoma and multiple myeloma.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.